Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis.

PAVLASOVÁ, Gabriela, Marek BORSKÝ, Václav ŠEDA, Kateřina ČERNÁ, Jitka OSIČKOVÁ, Michael DOUBEK, Jiří MAYER, R. CALOGERO, Šárka POSPÍŠILOVÁ, M. DAVIDS, J. BROWN and Marek MRÁZ. Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis. In Haematologica (2016); 101(s1): 47 (21st Congress of the EHA, Dánsko). 2016.

Basic information

• Original name: Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
• Authors: PAVLASOVÁ, Gabriela, Marek BORSKÝ, Václav ŠEDA, Kateřina ČERNÁ, Jitka OSIČKOVÁ, Michael DOUBEK, Jiří MAYER, R. CALOGERO, Šárka POSPÍŠILOVÁ, M. DAVIDS, J. BROWN and Marek MRÁZ.
• Edition: Haematologica (2016); 101(s1): 47 (21st Congress of the EHA, Dánsko), 2016.

Other information

• Type of outcome: Conference abstract
• Confidentiality degree: is not subject to a state or trade secret
• Organization unit: Central European Institute of Technology

Links

• LD15144, research and development project: Name: Buněčné a nebuněčné základy pro regeneraci kostí a zubů (Acronym: TissueENG)

Investor: Ministry of Education, Youth and Sports of the CR

• LQ1601, research and development project: Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

• MUNI/A/1028/2015, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit III (Acronym: VýDiTeHeMa III)

Investor: Masaryk University, Category A

• 16-29622A, interní kód MU(CEP code: NV16-29622A): Name: Vliv terapeutické inhibice BCR signalizace na genovou expresi u B buněčných malignit a její prognostický a prediktivní význam

Investor: Ministry of Health of the CR

• 692298, interní kód MU: Name: MEDGENET - Medical genomics and epigenomics network (Acronym: MEDGENET)

Investor: European Union, Spreading excellence and widening participation